13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240

  
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03350633
(ClinicalTrials.gov)
November 1, 201710/11/2017Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum DisordersSafety and Efficacy of Tocilizumab Versus Azathioprine in Neuromyelitis Optica Spectrum Disorders: a Randomized, Controlled, Open-label, Phase 2 TrialNeuromyelitis Optica Spectrum Disorders;Neuromyelitis OpticaDrug: Tocilizumab Injection;Drug: AzathioprineTianjin Medical University General HospitalNULLCompleted18 YearsN/AAll118Phase 2/Phase 3China
2NCT03062579
(ClinicalTrials.gov)
February 1, 201713/2/2017A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSDSingle-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD)Neuromyelitis Optica Spectrum Disorders;Neuromyelitis Optica;Devic's DiseaseDrug: TocilizumabFu-Dong ShiNULLCompleted18 YearsN/AAll10Phase 1/Phase 2China
3JPRN-UMIN000022201
2016/01/1004/05/2016The efficacy and safety of tocilizumab in patients with neuromyelitis opticaThe efficacy and safety of tocilizumab in patients with neuromyelitis optica - The efficacy and safety of tocilizumab in patients with neuromyelitis optica neuromyelitis opticaTocilizumab it to be infused every 4weeks at 8mg/kg of body weight for 2 years.Department of Neurology, Shimane University HospitalNULLComplete: follow-up complete20years-old74years-oldMale and Female3Not selectedJapan
4JPRN-UMIN000012705
2014/01/0707/01/2014The efficacy and safety of an anti-interluekin-6 receptor antibody in relapsing-remitting multiple sclerosis Relapsing-remitting multiple sclerosisTocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 2 years.Department of Immunology, National Institute of Neuroscience, NCNPNULLRecruiting20years-old65years-oldMale and Female10Not applicableJapan
5JPRN-jRCTs031180346
02/12/201318/03/2019Treatment with an anti-interleukin-6 receptor antibody for multiple sclerosisThe efficacy and safety of an anti-interluekin-6 receptor antibody in multiple sclerosis multiple sclerosis;D009103Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight.Yamamura TakashiNULLComplete>= 20age old<= 65age oldBoth6N/AJapan
6JPRN-jRCTs031180152
04/06/201225/02/2019Tocilizumab in patients with neuromyelitis opticaThe safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter study - Tocilizumab in patients with neuromyelitis optica Neuromyelitis optica;D009471Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 months.Yamamura TakashiNULLComplete>= 20age old<= 65age oldBoth20N/AJapan
7JPRN-UMIN000007866
2012/05/0101/05/2012The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter Study neuromyelitis opticaTocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 years.Department of Immunology, National Institute of Neuroscience, NCNPDepartment of Neurology, Kinki University Faculty of MediceineComplete: follow-up continuing20years-old65years-oldMale and Female15Not applicableJapan
8JPRN-UMIN000005889
2011/07/0108/07/2011The safety and efficacy of tocilizumab in patients with neuromyelitis optica neuromyelitis opticaTocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 months.Department of Immunology, National Institute of Neuroscience, NCNPNULLComplete: follow-up complete20years-old65years-oldMale and Female3Not applicableJapan